Weight-loss drugs are often sold—implicitly or explicitly—as if they simply “take away fat.” Personally, I think what this new body-composition evidence really forces us to confront is something more uncomfortable: when people lose weight quickly, their bodies don’t behave like obedient calculators. They spend muscle too, and the size of that muscle loss may be larger than many clinicians (and most patients) intuitively expect. From my perspective, the most worrying part isn’t the existence of muscle loss—it’s how long we’ve talked past the question of what that muscle loss means for real life.
The promise isn’t the problem
The headline takeaway from the presented systematic review is that incretin-based obesity therapies lead to more muscle loss than the typical clinical expectations during weight reduction. Specifically, the research reported that a large majority of participants exceeded a commonly anticipated 25% muscle-loss threshold, and that this happened more often than in lifestyle or placebo groups. Personally, I think the reason this feels like a “betrayal” to some readers is psychological: modern medicine has conditioned people to treat breakthroughs as linear wins, where benefits arrive neatly packaged and side effects are either small or predictable. But the body is not a vending machine; it’s a dynamic system with competing priorities.
What makes this particularly fascinating is that muscle loss is being detected through body-composition methods (including DEXA, CT, and MRI), not through “functional decline” endpoints like strength testing or mobility metrics. In my opinion, that distinction is everything, because muscle mass and muscle function are related—but not identical. People usually misunderstand this by assuming that “lean mass goes down” automatically means “function collapses,” either catastrophically or not at all. The truth is more nuanced: muscle quality, neuromuscular coordination, and training/behavior changes can matter as much as raw tissue quantity.
The clinical blind spot
A detail that I find especially interesting is what the investigators—and independent clinicians—say is missing: direct measurement of whether greater muscle loss actually translates into weaker performance or worse function. This leaves clinicians in a position that’s intellectually unsatisfying: we can quantify tissue changes, but we can’t yet fully quantify the lived consequences. From my perspective, this is a classic “phase mismatch” in medicine—labs and imaging move faster than outcome science.
What this really suggests is that healthcare conversations are currently too focused on weight numbers and not focused enough on capability. Jaime Almandoz’s point about lean mass not necessarily equaling skeletal muscle quality function or health resonates with my own instincts as a commentator: muscle is not just an anatomical inventory; it’s an engine that powers balance, independence, and long-term metabolic resilience. And if you take a step back and think about it, function is the currency older adults actually spend. People can survive weight loss; they often cannot survive loss of mobility.
Age changes the stakes
Here’s where my viewpoint becomes more pointed: for younger adults, a hit to muscle mass might be a short-term tradeoff; for older adults, it can be a long-term liability. The evidence discussed includes very few older participants—only a small fraction were 60+—and none were focused on adults 65+. Personally, I think that matters because age-related muscle decline (sarcopenia) already exists as background noise, meaning any added reduction is not happening in a vacuum.
This raises a deeper question: are we optimizing these therapies for the people who look most like the study populations, even if the real-world majority of patients who struggle with obesity and frailty are older? What many people don't realize is that clinical trial inclusion criteria can unintentionally shape clinical expectations. If you don’t enroll enough older adults, you don’t just lack data—you risk adopting a “one-size-fits-most” mindset. And in geriatric medicine, mindset is not a philosophical issue; it becomes a practical one when someone’s grip strength, gait, or ability to stand from a chair defines independence.
Why the 25% benchmark matters (and why it doesn’t)
The study appears to use a 25% muscle-loss threshold that clinicians generally anticipate during weight reduction. Personally, I think that’s a useful anchor because it gives people something concrete to compare against, rather than vague fears. But I also think benchmarks can seduce us into false confidence. Exceeding a threshold doesn’t automatically mean someone will lose function—especially if the person is also exercising, improving diet quality, or benefiting from other metabolic changes.
From my perspective, the real danger is not “25%” itself; it’s the gap between tissue-level change and outcome-level change. If we only track mass, we risk optimizing weight loss while accidentally under-investing in preserving the machinery needed to use that weight loss safely. The body can lose fat and still become less capable if muscle and strength aren’t protected. People tend to misunderstand this because they think health is primarily scale weight, when for many patients health is the ability to live—walk, work, cook, climb stairs, and avoid falls.
What clinicians can do now
Although the functional link is not fully established, the experts highlighted practical steps clinicians can implement immediately—especially simple, equipment-light strength and mobility assessments. The suggestions include tracking grip strength, sit-to-stand performance, timed up-and-go, gait speed, and chair-stand tests. Personally, I think this is the right direction because it acknowledges uncertainty without becoming passive. You can’t wait for perfect data to start asking the better questions.
If you’re looking for a mindset shift, it’s this: muscle preservation should be treated as part of the prescription, not as an afterthought. In my opinion, referrals to physical therapists, exercise specialists, and nutritionists should be normalized rather than reserved for the “most motivated” patients. What this implies is that weight-loss pharmacology may need to be paired with muscle-oriented care the way diabetes medication is paired with glucose monitoring. You don’t just prescribe insulin or GLP-1 therapy and hope the rest takes care of itself.
The benefits shouldn’t be ignored
Now, let me be clear: my critique isn’t “these drugs are bad.” The evidence and commentary described also acknowledge strong benefits—reduced cardiovascular risk, improved cardiometabolic health, and better quality of life. Personally, I think that balance is crucial, because the public debate around obesity drugs often flips between two extremes: either they’re miracle cures or they’re ticking time bombs. The honest take is more demanding: the benefits are real, but the clinical job is to ensure the benefits are the ones we want.
What this really suggests is that the next phase of obesity medicine isn’t about whether incretin-based therapies work for weight loss. It’s about whether the weight loss is “predominantly fat” while preserving muscle needed for metabolic health, physical function, and healthy aging. I find that framing especially interesting because it forces medicine to define success beyond appearance and beyond scale metrics. It turns the question from “Did you lose weight?” into “Did you get healthier in the ways that matter long-term?”
What future trials must answer
If you want to know where this field should go next, the editorial commentary and accompanying discussion point toward specific trial improvements: include more older adults, standardize muscle-related outcome measures, and directly track function and mobility outcomes. Personally, I think future studies need to treat strength and performance metrics as co-primary endpoints, not as optional add-ons.
From my perspective, this is also where technology and behavior should converge. Body-composition imaging can tell us what tissue changed; strength and mobility testing can tell us what that change cost (or didn’t cost). And training interventions—whether structured resistance exercise or targeted physical therapy—may reveal whether the muscle loss observed in imaging studies can be mitigated in real life. People often underestimate how much exercise can change the “meaning” of lost mass, because the body adapts.
Bottom line
One thing that immediately stands out is that we now have evidence of unexpectedly large muscle loss with incretin-based obesity drugs, but we still lack definitive data linking that loss to strength and functional decline across the populations most at risk. Personally, I think this is precisely the moment for a more mature conversation: keep the benefits, tighten the monitoring, and redesign care so muscle preservation is treated as a clinical outcome.
If we take this seriously, we won’t just be reducing obesity—we’ll be protecting the physical capacity that allows weight loss to translate into a longer, safer, more independent life.
